Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ · Manufacturing · Pharmaceutical preparations
RYTM price, last 12 months
Key stats
- Previous close
- $98.31
- Open
- $98.41
- Day range
- $96.35 – $99.45
- 52-week range
- $74.50 – $122.20
- Volume
- 758.5K
- Avg volume (20 days)
- 619.9K
- Market cap
- $6.8B
Performance
Technicals and fundamentals
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $6.8B